MEDU-23. IMPROVING IMMUNOTHERAPEUTIC POTENTIAL IN GROUP 3 MEDULLOBLASTOMA USING LOW DOSE RADIATION FOLLOWED BY 4-1BB MONOCLONAL ANTIBODY ADMINISTRATION

INTRODUCTION: Group 3 Medulloblastoma (MB) subtype has the worst prognosis amongst the MB subtypes. Despite aggressive treatments, survival of patients with Group 3 MB remains below 50% over 5 years. A limitation of therapeutic success is cancer cellular mechanisms suppressing immune responses, enab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Alshareef, Mohammed, Eskandari, Ramin, McDonald, Daniel, Vanek, Kenneth, Jenrette, Joseph, Patel, Sunil, Cheshier, Samuel, Cachia, David, Das, Arabinda
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Medulloblastoma
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477389/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados